Search Results - "Ward, Richard A."

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer by Cross, Darren A E, Ashton, Susan E, Ghiorghiu, Serban, Eberlein, Cath, Nebhan, Caroline A, Spitzler, Paula J, Orme, Jonathon P, Finlay, M Raymond V, Ward, Richard A, Mellor, Martine J, Hughes, Gareth, Rahi, Amar, Jacobs, Vivien N, Red Brewer, Monica, Ichihara, Eiki, Sun, Jing, Jin, Hailing, Ballard, Peter, Al-Kadhimi, Katherine, Rowlinson, Rachel, Klinowska, Teresa, Richmond, Graham H P, Cantarini, Mireille, Kim, Dong-Wan, Ranson, Malcolm R, Pao, William

“…First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical benefit in patients with advanced EGFR-mutant (EGFRm(+)) non-small…”
Get more information

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions by Floc'h, Nicolas, Martin, Matthew J, Riess, Jonathan W, Orme, Jonathan P, Staniszewska, Anna D, Ménard, Ludovic, Cuomo, Maria Emanuela, O'Neill, Daniel J, Ward, Richard A, Finlay, M Raymond V, McKerrecher, Darren, Cheng, Mingshan, Vang, Daniel P, Burich, Rebekah A, Keck, James G, Gandara, David R, Mack, Philip C, Cross, Darren A E

“…EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non-small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally…”
Get full text

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR) by Ward, Richard A, Anderton, Mark J, Ashton, Susan, Bethel, Paul A, Box, Matthew, Butterworth, Sam, Colclough, Nicola, Chorley, Christopher G, Chuaqui, Claudio, Cross, Darren A. E, Dakin, Les A, Debreczeni, Judit É, Eberlein, Cath, Finlay, M. Raymond V, Hill, George B, Grist, Matthew, Klinowska, Teresa C. M, Lane, Clare, Martin, Scott, Orme, Jonathon P, Smith, Peter, Wang, Fengjiang, Waring, Michael J

“…A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase,…”
Get full text

Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations by Avizienyte, Egle, Ward, Richard A, Garner, Andrew P

“…Recent clinical data indicates that the emergence of mutant drug-resistant kinase alleles may be particularly relevant for targeted kinase inhibitors. In order…”
Get more information

Structural basis of the effect of activating mutations on the EGF receptor by Galdadas, Ioannis, Carlino, Luca, Ward, Richard A, Hughes, Samantha J, Haider, Shozeb, Gervasio, Francesco Luigi

“…Mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are common oncogenic driver events in non-small cell lung cancer. Although…”
Get full text

Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily by Wrigley, Jonathan D, Gavory, Gerald, Simpson, Iain, Preston, Marian, Plant, Helen, Bradley, Jenna, Goeppert, Anne U, Rozycka, Ewelina, Davies, Gareth, Walsh, Jarrod, Valentine, Andrea, McClelland, Keeva, Odrzywol, Krzysztofa Ewa, Renshaw, Jonathan, Boros, Joanna, Tart, Jonathan, Leach, Lindsey, Nowak, Thorsten, Ward, Richard A, Harrison, Timothy, Andrews, David M

“…The ubiquitin proteasome system is widely postulated to be a new and important field of drug discovery for the future, with the ubiquitin specific proteases…”
Get full text

The Design of Covalent-Based Inhibitors by Ward, Richard A, Grimster, Neil

“…Annual Report on Medicinal Chemistry series, highlights new advances in the field with this new volume presenting interesting chapters. Each chapter is written…”
Get full text

Re-Examining Neutrophil Participation in GN by Caster, Dawn J, Powell, David W, Miralda, Irina, Ward, Richard A, McLeish, Kenneth R

“…Significant advances in understanding the pathogenesis of GN have occurred in recent decades. Among those advances is the finding that both innate and adaptive…”
Get full text

Granule exocytosis contributes to priming and activation of the human neutrophil respiratory burst by Uriarte, Silvia M, Rane, Madhavi J, Luerman, Gregory C, Barati, Michelle T, Ward, Richard A, Nauseef, William M, McLeish, Kenneth R

“…The role of exocytosis in the human neutrophil respiratory burst was determined using a fusion protein (TAT-SNAP-23) containing the HIV transactivator of…”
Get full text

Proteomic Analysis of Human Neutrophil Granules by Lominadze, George, Powell, David W, Luerman, Greg C, Link, Andrew J, Ward, Richard A, McLeish, Kenneth R

“…Stimulated exocytosis of intracellular granules plays a critical role in conversion of inactive, circulating neutrophils to fully activated cells capable of…”
Get full text

Extracorporeal Removal of Uremic Toxins: Can We Still Do Better? by Eloot, Sunny, PhD, Ledebo, Ingrid, PhD, Ward, Richard A., PhD

“…Summary Improving outcomes by manipulating the prescription of renal replacement therapy to increase the removal of uremic toxins has had limited success…”
Get full text

Endocytosis is required for exocytosis and priming of respiratory burst activity in human neutrophils by Creed, T. Michael, Tandon, Shweta, Ward, Richard A., McLeish, Kenneth R.

“…Objective and design Neutrophil generation of reactive oxygen species (ROS) is enhanced by exposure to pro-inflammatory agents in a process termed priming…”
Get full text

Challenges and Opportunities in Cancer Drug Resistance by Ward, Richard A, Fawell, Stephen, Floc’h, Nicolas, Flemington, Vikki, McKerrecher, Darren, Smith, Paul D

“…There has been huge progress in the discovery of targeted cancer therapies in recent years. However, even for the most successful and impactful cancer drugs…”
Get full text

Technical note: proteomic approaches to fundamental questions about neutrophil biology by McLeish, Kenneth R., Merchant, Michael L., Klein, Jon B., Ward, Richard A.

“…Review of technologic advances that examine proteomics and its significant contributions to the understanding of neutrophil biology. Proteomics is one of a…”
Get full text

Inhibition of neutrophil exocytosis ameliorates acute lung injury in rats by Uriarte, Silvia M, Rane, Madhavi J, Merchant, Michael L, Jin, Shunying, Lentsch, Alex B, Ward, Richard A, McLeish, Kenneth R

“…Exocytosis of neutrophil granules contributes to acute lung injury (ALI) induced by infection or inflammation, suggesting that inhibition of neutrophil…”
Get full text

The actin cytoskeleton regulates exocytosis of all neutrophil granule subsets by Jog, Neelakshi R, Rane, Madhavi J, Lominadze, George, Luerman, Gregory C, Ward, Richard A, McLeish, Kenneth R

“…A comprehensive analysis of the role of the actin cytoskeleton in exocytosis of the four different neutrophil granule subsets had not been performed…”
Get more information

Comparison of Proteins Expressed on Secretory Vesicle Membranes and Plasma Membranes of Human Neutrophils by Uriarte, Silvia M, Powell, David W, Luerman, Gregory C, Merchant, Michael L, Cummins, Timothy D, Jog, Neelakshi R, Ward, Richard A, McLeish, Kenneth R

“…Secretory vesicles are neutrophil intracellular storage granules formed by endocytosis. Understanding the functional consequences of secretory vesicle…”
Get full text

Basic prerequisites for on‐line, high‐volume hemodiafiltration by Ward, Richard A.

“…High‐volume hemodiafiltration involves filtration of >23 L/treatment and its replacement by sterile non‐pyrogenic substitution fluid, while maintaining the…”
Get full text

Membrane innovation: closer to native kidneys by Storr, Markus, Ward, Richard A

“…Modern methods in analytical biochemistry have established that uraemia is associated with the retention of proteins, both in their native state and…”
Get full text

Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies by Zhai, Xiang, Ward, Richard A, Doig, Peter, Argyrou, Argyrides

“…Osimertinib is a covalent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for treating non-small cell lung…”
Get full text